Cancer Research Horizons
Amanda Ferdinand is an experienced scientist who specializes in assay development and compound profiling. Amanda has worked at Cancer Research Technology and currently works at Cancer Research Horizons. Amanda's research background includes investigating erythroid enucleation during their PhD at the University of Bristol. Amanda also gained valuable skills in neurodegeneration research during a placement at Eli Lilly and Company. Amanda holds a PhD in Cell/Cellular and Molecular Biology from the University of Bristol and a Bachelor of Science in Biochemistry from the University of Bath.
This person is not in any teams
Cancer Research Horizons
Cancer Research Horizons is Cancer Research UK's innovation engine. We take scientific breakthroughs from the lab bench to the bedside, translating them into effective treatments and diagnostics for cancer patients. To date, we’ve played an instrumental role in forming over 60 spin-out companies and bringing 11 new cancer drugs to market, borne out of our pioneering research. We are the second biggest licensor of cancer research treatments globally and are part of Cancer Research UK – the world’s largest medical research charity. With exclusive rights to over £300m of world-class cancer research we’re a unique and powerful partner in the fight to beat cancer. We work closely with academia and industry to bridge the gap between research and the market, delivering maximum impact for patients. Every penny we make goes back into developing the next breakthroughs, helping bring forward the day when all cancer is conquered.